HIV 1 News and Research

RSS

NeurogesX plans U.S. label expansion for Qutenza in HIV-associated neuropathy

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced plans to pursue a U.S. label expansion for Qutenza® (capsaicin) 8% patch to include patients with painful HIV-associated neuropathy (HIV-AN, also referred to as HIV-distal sensory polyneuropathy (HIV-DSP)).

19 Oct 2010

The state of sexually transmissible and blood-borne infections in Australia: the 2010 Surveillance Reports

Australia last year reported its largest number of new HIV cases since the early 1990s but has seen a reduction in cases of hepatitis, infectious syphilis and gonorrhoea, new data contained in HIV, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2010 shows.

18 Oct 2010

The future face of HIV in Australia

The profile of people living with HIV in Australia is set to change significantly over the next decade. Among these changes are increases in new HIV infections; increases in the number of older men and women living with HIV; and a greater proportion of people with HIV living outside major metropolitan areas.

18 Oct 2010

GeoVax Labs contributes article for HIV vaccine

Robert T. McNally, Ph.D., president and CEO of GeoVax Labs, Inc. a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, has contributed an article on the search for an HIV vaccine to the October 15 issue of Genetic Engineering & Biotechnology News (GEN).

18 Oct 2010

HHS awards $4.8 million grant for Teen Prevention Education Program

The Princeton Center for Leadership Training (PCLT), in collaboration with long-time partner HiTOPS, was awarded a five-year, $4.8 million federal grant from the U.S. Department of Health and Human Services (HHS) to replicate and evaluate a teen sexual health peer education program, known as the Teen Prevention Education Program (Teen PEP), in 16 high schools in rural North Carolina communities with high teen birth rates.

18 Oct 2010

NanoViricides' President delivers speech at ASNM Second Annual Conference

NanoViricides, Inc. announced today that the Company President was invited to and presented a talk at the Second Annual Conference of the American Society for NanoMedicine (ASNM).

18 Oct 2010

Phase III study influences WHO to change guidelines for HIV-infected women receiving nevirapine

Findings from a study, which appear in the Oct. 14, 2010 New England Journal of Medicine, helped influence the World Health Organization (WHO) to change its guidelines this year for the treatment of HIV-infected women who receive a single dose of the antiretroviral drug nevirapine to prevent HIV transmission to their babies.

18 Oct 2010

Major advance in treatment of brain disorders with external genes

In the October 17 issue of Nature Methods, researchers at Thomas Jefferson University describe how they can transfer genes into brain neurons intravenously, using a viral gene delivery vehicle (vector) that causes no side effects.

18 Oct 2010

CDC: Hispanics more likely to have HIV than whites, but live longer

The Associated Press: Officials from the Centers for Disease Control and Prevention "estimate that 1 in 22 black Americans will be diagnosed with the AIDS virus in their lifetime — more than twice the risk for Hispanics and eight times that of whites. ... the lifetime risk is 1 in 52 for Hispanics, and 1 in 170 for whites. Asian-Americans had the lowest lifetime risk, at about 1 in 222" (10/14).

15 Oct 2010

First Edition: October 15, 2010

Today's top stories from major news organizations report on the effort by 20 states to challenge the federal health law, a new federal panel to inform consumers about health care options and the struggle to pay for cancer care.

15 Oct 2010

Scientists to monitor effectiveness of Streptococcus vaccine

Respiratory infections and diarrhoeal diseases kill approximately four million children each year, with most deaths occurring in developing countries. New vaccines for Streptococcus pneumoniae, a bacterium that causes pneumonia, and rotavirus, the most common cause of severe diarrhoea, have proved successful in preventing the development of the diseases in clinical trials, but have yet to be used routinely in many parts of Africa.

15 Oct 2010

Issuing first report on NTDS, WHO aims for 'complete control' by 2015

The WHO said on Thursday that it was aiming for 'complete control' by 2015 of tropical diseases that affect one billion impoverished people and kill an estimated 534,000 people each year, Agence France-Presse reports.

15 Oct 2010

New insights into HIV infection process may allow antiviral drug development

New insights into the human immunodeficiency virus (HIV) infection process, which leads to acquired immunodeficiency syndrome (AIDS), may now be possible through a research method recently developed in part at the National Institute of Standards and Technology (NIST), where scientists have glimpsed an important protein molecule's behavior with unprecedented clarity.

15 Oct 2010

SAMHSA awards grants to provide integrated substance abuse and HIV/AIDS prevention services

The Substance Abuse and Mental Health Services Administration is awarding up to $52.5 million for up to five years in cooperative agreements (grants) to provide integrated substance abuse and HIV/AIDS prevention services to at-risk, traditionally underserved populations.

15 Oct 2010

Reuters examines experts' concerns about global polio eradication effort

Reuters examines the global effort to eradicate polio and how failure to eliminate the disease could affect future global health undertakings.

15 Oct 2010

NanoViricides files financial year end annual report with SEC

NanoViricides, Inc. reports that it has filed its financial year end annual report (Form 10K) with the Securities and Exchange Commission (SEC) yesterday in a timely manner.

14 Oct 2010

World's third rectal microbicide trial launched in Pittsburgh

The world's third rectal microbicide trial launched in Pittsburgh, Pennsylvania today, with sites preparing to open in Boston, Massachusetts, and Birmingham, Alabama soon. Scientists will test the rectal safety and acceptability of tenofovir gel, a microbicide developed for vaginal use that has shown promise for preventing HIV through vaginal intercourse. Depending on the outcome of this new study, tenofovir gel could be further evaluated to determine if it can reduce the risk of HIV among both men and women who engage in receptive anal intercourse.

14 Oct 2010

Stop TB Partnership launches Global Plan to Stop TB 2011-2015

The WHO's Stop TB Partnership "laid out a new plan on Wednesday to combat tuberculosis and the nearly 2 million deaths it causes each year," Reuters reports.

14 Oct 2010

New global plan for elimination of TB

The world could be on its way towards eliminating tuberculosis (TB) if governments and donors fully invest in a plan released today by the Stop TB Partnership. The global plan to stop TB 2011-2015: transforming the fight towards elimination of tuberculosis for the first time identifies all the research gaps that need to be filled to bring rapid TB tests, faster treatment regimens and a fully effective vaccine to market.

13 Oct 2010

ViiV Healthcare to expand Patient Assistance Program

ViiV Healthcare will expand its Patient Assistance Program effective January 1, 2011 and continue its Patient Savings Card program to help maintain access to HIV medicines for those most affected by the economic downturn in the United States. Specifically, ViiV Healthcare will launch the ViiV Healthcare Patient Assistance Program with an increased maximum household income level for enrollment and is piloting membership in the Welvista program, a nonprofit program to facilitate access to HIV medications for individuals currently on ADAP waiting lists.

13 Oct 2010